- Drug Discovery has historically been the most expensive and lengthy step in creating new drugs. SDGR's physics-based software cuts the time in half as well as the costs.
- Along with being a software company with 80% GMs, 99% customer retention rate and robust growth, they have their preclinical drug pipeline giving them major upside.
- Bill Gates and billionaire healthcare tech hedge fund titan David E. Shaw are early investors and currently own ~27% of the outstanding shares.
For further details see:
Schrodinger: High Margins, Sticky Business, Incredible Upside